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Nuclear gene mutations as the cause
of mitochondrial complex III
deficiency
Erika Fernández-Vizarra*† and Massimo Zeviani
Mitochondrial Biology Unit, Medical Research Council, Cambridge, UK
Complex III (CIII) deficiency is one of the least common oxidative phosphorylation defects
associated to mitochondrial disease. CIII constitutes the center of the mitochondrial
respiratory chain, as well as a crossroad for several other metabolic pathways. For
more than 10 years, of all the potential candidate genes encoding structural subunits
and assembly factors, only three were known to be associated to CIII defects in
human pathology. Thus, leaving many of these cases unresolved. These first identified
genes were MT-CYB, the only CIII subunit encoded in the mitochondrial DNA; BCS1L,
encoding an assembly factor, and UQCRB, a nuclear-encoded structural subunit.
Nowadays, thanks to the fast progress that has taken place in the last 3–4 years,
pathological changes in seven more genes are known to be associated to these
conditions. This review will focus on the strategies that have permitted the latest
discovery of mutations in factors that are necessary for a correct CIII assembly and
activity, in relation with their function. In addition, new data further establishing the
molecular role of LYRM7/MZM1L as a chaperone involved in CIII biogenesis are
provided.
Keywords: oxidative phosphorylation (OXPHOS), mitochondrial diseases, genetic mutations, complex III
deficiency, complex III assembly
Introduction
Within the group of mitochondrial diseases or more speciﬁcally, OXPHOS disorders, isolatedmito-
chondrial complex III (CIII) deﬁciencies are among the least frequently diagnosed. It is possible
that these deﬁcits are not rarer than those of the other complexes, but their diagnosis may be more
diﬃcult due to the lack of histological and biochemical hallmarks in skeletal muscle biopsies, e.g.,
no COX negative or ragged red ﬁbers (DiMauro et al., 2013). Also, diﬀerent protocols used in dif-
ferent labs to measure CIII enzymatic activity can also introduce some bias to detect defects (Medja
et al., 2009). Typical to mitochondrial syndromes, CIII defects are associated with a wide range of
clinical presentations, the only common feature being the reduced ubiquinol:cytochrome c oxi-
doreductase enzymatic activity measured in samples from the subjects under study. The defective
factor responsible for CIII malfunction and thus, the molecular pathogenic mechanisms are also
widely variable.
Complex III or cytochrome bc1 complex forms the central part of the mitochondrial respi-
ratory chain, oxidizing coenzyme Q and reducing cytochrome c while pumping protons from
the matrix to the intermembrane space through the so-called Q-cycle mechanism (Crofts et al.,
2008). Mammalian CIII is a multiheteromeric enzyme composed of eleven diﬀerent subunits
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(Schagger et al., 1986), one encoded by mitochondrial DNA
(mtDNA) and ten by nuclear genes. These eleven subunits con-
stitute the monomeric module of a symmetric dimer (CIII2),
which constitutes the functionally active form of the enzyme.
The complex is embedded in the mitochondrial inner membrane,
spanning from the matrix to the inter-membrane space. The crys-
tal structure (Xia et al., 1997; Iwata et al., 1998) diﬀers from
the ones of yeast (Hunte et al., 2000) and chicken (Zhang et al.,
1998) only because it contains one additional subunit. This extra
subunit (Subunit 9) is just the mitochondrial targeting sequence
peptide of the Rieske Fe-S protein, which is incorporated into
the complex after its cleavage during import into the organelle
(Brandt et al., 1993). Three of the 11 subunits contain the cat-
alytic centers: cytochrome b (MT-CYB), cytochrome c1 (CYC1)
and the Rieske protein (UQCRFS1). Cytochrome b contains two
heme moieties, the low potential (bL) and the high potential (bH)
heme b; CYC1 binds a c-type heme group and the Rieske iron-
sulfur protein contains a 2Fe-2S cluster. The exact function of
the other eight supernumerary subunits (UQCRC1, UQCRC2,
UQCRH, UQCRB, UQCRQ, Subunit 9, UQCR10 and UQCR11)
remains to be established (Xia et al., 2013).
The proteins needed for transcription and translation of MT-
CYB, as well as CIII assembly factors, are all encoded by nuclear
genes.
Cytochrome bc1 assembly has beenmainly studied in the yeast
Saccharomyces cerevisiae. Yeast deletion mutants have proved
to be an extremely useful tool to discover proteins involved in
CIII and CIV biogenesis. By using yeast as a model organism,
a great deal of CIV assembly factors have been discovered dur-
ing the last two decades, and the assembly of this enzyme is
known in mechanistic detail (Mick et al., 2011; Soto et al., 2012).
Although investigation on CIII biogenesis has been far less assid-
uous, models of CIII assembly in yeast have been developed in
the last years (Zara et al., 2004, 2007, 2009b; Gruschke et al.,
2011, 2012; Hildenbeutel et al., 2014). According to these mod-
els, the diﬀerent structural subunits start gathering inside several
subcomplexes that afterward join to form a pre-CIII. The com-
plex ﬁnally matures and becomes active with the addition of the
Rieske protein, which is the second to last subunit to be incor-
porated. A complete understanding on how this incorporation
occurs has already been achieved in yeast (Wagener et al., 2011).
Thus, in addition to the structural subunits, another set of pro-
teins are involved in the process acting as chaperones, which bind
individual subunits or assembly intermediates to stabilize them,
or as assembly factors, who act to incorporate subunits during
the pathway (Smith et al., 2012). CIII assembly in humans is
deemed to be similar to that in yeast (Figure 1), given the struc-
tural similarity between yeast and mammalian CIII and because
several orthologs of yeast assembly factors have been identiﬁed
in humans as well (Petruzzella et al., 1998; Sanchez et al., 2013;
Tucker et al., 2013; Wanschers et al., 2014). However, mecha-
nistic details have been experimentally proven only for a few
steps of human CIII assembly. The initial step is the release of
MT-CYB from the mitoribosome and its insertion into the mito-
chondrial inner membrane, a process that requires two assembly
factors, UQCC1 and UQCC2 (Tucker et al., 2013). A much
later step has also been deﬁned in humans, consisting in the
incorporation of the Rieske protein (UQCRFS1), operated by the
assembly factor, BCS1L, into a nearly complete dimeric but inac-
tive pre-complex III (pre-CIII2; Fernandez-Vizarra et al., 2007;
Hinson et al., 2007; Gil-Borlado et al., 2009). The exact mech-
anism has not been studied in detailed in human systems, but
the evidences point to a very similar process as the one in yeast
mitochondria. However, there is still very limited information
about the intermediate steps, i.e., how the pre-CIII2 stage is
achieved.
Until 2008, mutations in only three genes were known to be
associated with CIII deﬁciency (Benit et al., 2009; Fernandez-
Vizarra et al., 2009). The ﬁrst to be detected were in MT-CYB
(OMIM 516020), initially described in the late 1990’s (Andreu
et al., 1998, 1999a,b, 2000; De Coo et al., 1999; Keightley et al.,
2000). These were usually sporadic mutations causing myopa-
thy and exercise intolerance. Then, mutations in the nuclear
gene BCS1L were found in CIII-deﬁcient patients (de Lonlay
et al., 2001). Defective BCS1L is still the most frequent cause of
CIII-defective mitochondrial disease, as more than 25 diﬀerent
pathological mutations associated to very variable clinical presen-
tations have been described (Table 3). Finally, a mutation in the
UQCRB gene was found in a subject with hepatopathy and CIII
deﬁciency (Haut et al., 2003). Since then, the introduction of next
generation sequencing (NGS) techniques and the identiﬁcation of
additional assembly factors in yeast (Cruciat et al., 1999; Atkinson
et al., 2010; Gruschke et al., 2011, 2012; Mathieu et al., 2011; Cui
et al., 2012) corresponding to orthologs in humans, has led to
the identiﬁcation of sevenmore CIII-disease genes. Three encode
CIII structural subunits: UQCRQ (Barel et al., 2008), UQCRC2
(Miyake et al., 2013), CYC1 (Gaignard et al., 2013) whereas the
remaining four encode assembly factors: TTC19 (Ghezzi et al.,
2011), LYRM7 (Invernizzi et al., 2013), UQCC2 (Tucker et al.,
2013) and UQCC3 (Wanschers et al., 2014). All of the muta-
tions in nuclear genes follow an autosomal recessive pattern of
inheritance.
This review will describe in detail each of the nuclear-encoded
proteins in which mutations have been found to be associated to
CIII deﬁciency (summarized in Table 1) in relation to their func-
tion and the clinical presentations of the patients suﬀering from
this condition. In an attempt to explain the molecular patho-
logical mechanisms found in the patients we will relate them to
the role of the speciﬁc protein within the assembly process, bear-
ing in mind that most of the information was obtained in the S.
cerevisiae system.
Structural Subunits
UQCRB
The daughter of healthy consanguineous Turkish parents is the
only known case of CIII deﬁciency caused by a mutation in the
UQCRB gene, located on chromosome 8q22 (OMIM 191330).
UQCRB encodes the human ubiquinone-binding protein of CIII
(QP-C subunit or subunit VI; Haut et al., 2003). The girl was
born and developed normally until 8 months of age when she
presented with acute gastroenteritis. She showed liver enlarge-
ment and blood tests revealed mildly elevated hepatic enzymes,
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FIGURE 1 | Human complex III assembly model. The model is
constructed by homology with the available data for S. cerevisiae (Zara et al.,
2007, 2009a,b; Atkinson et al., 2011; Gruschke et al., 2011, 2012; Wagener
et al., 2011; Cui et al., 2012; Smith et al., 2012; Hildenbeutel et al., 2014).
The names of the proteins mutated in CIII-deficiency cases are in red. First,
MT-CYB is translated in the mitochondrial ribosomes to which UQCC1 and
UQCC2 are bound to the exit tunnel, activating its synthesis. The
UQCC1-UQCC2 complex remains bound to MT-CYB once it is completely
synthesized and incorporated to the mitochondrial inner membrane. Once
low-potential heme b (bL) is inserted into the catalytic center of cytochrome b,
UQCC3 binds to it and then the high potential heme b (bH) is incorporated.
The UQCC1-UQCC2 dimer is released when UQCRB and UQCRQ bind to
MT-CYB, to form the early-stage CIII intermediary, so that UQCC1-UQCC2
dimer becomes available to activate translation of new MT-CYB by binding to
the mitoribosome. This system provides a way of regulating MT-CYB
translation related to its assembly into CIII. After the formation of the early
intermediate MT-CYB+UQCRB+UQCRQ, additional subunits, i.e., UQCRC1,
UQCRC2, and CYC1 are incorporated, followed by UQCRH and later
UQCR10, to form pre-complex III (pre-CIII2 ). At this point, the complex is
already dimeric, but the precise stage at which dimerization occurs is currently
unknown. Finally, UQCRFS1 is translocated from the matrix into the inner
mitochondrial membrane and is incorporated into pre-CIII2. In the matrix,
UQCRFS1 is bound and stabilized by MZM1L. Finally the last subunit
(UQCR11) joins the nascent complex, so that assembly is completed. TTC19
is necessary for the correct biogenesis of CIII2 in human mitochondria, but
the step in which it intervenes is not known yet.
hypoglycemia, metabolic acidosis due to high blood lactate lev-
els that increased during metabolic crises. Isolated CIII deﬁciency
was detected in lymphocytes, skin ﬁbroblasts and in a liver biopsy.
Furthermore, the amount of cytochrome b was greatly reduced in
mitochondria isolated from ﬁbroblasts. The child was reported to
have undergone good clinical recovery, with neither psychomo-
tor nor other neurological impairment. Genetic analyses showed
a homozygous 4-bp deletion (nucleotides 338–341) in exon 4 of
the UQCRB gene, which predicts the synthesis of an abnormal
amino acid stretch at the C-terminal end in a highly conserved
portion of the protein. Both parents were heterozygous for the
same mutation, which was absent in 55 control individuals.
UQCRB is the homolog of the yeast Qcr7 subunit, which is
located in the matrix-inner mitochondrial membrane interphase
and is deemed to interact with cytochrome b in early stages
of the assembly pathway (Zara et al., 2009a; Figure 1). Qcr7
incorporation is essential to stabilize hemylated cytochrome b
(Hildenbeutel et al., 2014). By analogy, UQCRB must be impor-
tant for MT-CYB stability, which would explain the low amounts
of b-type cytochrome found in the patient mitochondria.
UQCRQ
UQCRQ is a nuclear gene located on chromosome 5q31, which
encodes a 9.5 kDa structural subunit of CIII, UQCRQ, also
termed subunit VII (OMIM 612080). A deleterious, autosomal
recessive mutation consisting of a c.208C > T transition in exon
2 of UQCRQ, determining a p.Ser45Phe amino acid change, was
found in 25 aﬀected members of a large consanguineous Israeli
Bedouin kindred (Barel et al., 2008). All the aﬀected individu-
als appeared normal at birth but showed delayed development
during the ﬁrst months of life, followed by the development of
severe Leigh-like syndrome with profound mental and extrapyra-
midal signs. Reduced CIII activity was found in skeletal muscle of
the probands. Albeit severe and early-onset, the clinical course
was progressive, with some individuals still being alive in their
thirties.
UQCRQ is embedded in the mitochondrial inner membrane,
in close contact to MT-CYB deep in the CIII backbone struc-
ture (Iwata et al., 1998). Its yeast homolog, Qcr8, was proposed
to form the early cytochrome b subcomplex together with Qcr7
(Zara et al., 2009a; Figure 1).
Frontiers in Genetics | www.frontiersin.org 3 April 2015 | Volume 6 | Article 134
Fernández-Vizarra and Zeviani Mitochondrial complex III deficiencies
TABLE 1 | Summary of the proteins encoded in the nuclear genome in
which mutations have been associated to Mitochondrial Complex III
Deficiency.
Protein Yeast
ortholog
Molecular role OMIM
number
Structural subunits
UQCRB Qcr7 Supernumerary subunit 191330
UQCRQ Qcr8 Supernumerary subunit 612080
UQCRC2 Qcr2 (Cor2) Supernumerary subunit 191329
CYC1 Cyt1 Catalytic subunit 123980
Accessory factors
TTC19 – Unknown 613814
BCS1L Bcs1 UQCRFS1 translocase 603647
LYRM7/MZM1L Mzm1 UQCRFS1
chaperone
615831
UQCC2 Cbp6 MT-CYB translational activator
and chaperone
614461
UQCC3 Cbp4 MT-CYB chaperone –
UQCRC2
Linkage analysis and whole-exome sequencing allowed the iden-
tiﬁcation of a pathological mutation in the UQCRC2 gene,
located on chromosome 16p2, encoding the CIII Core 2 protein
(also termed subunit II; OMIM 191329). The same homozy-
gous nucleotide mutation, (c.547C>T) leading to a p.Arg183Trp
amino acid change, was found in three members of a Mexican
consanguineous family (Miyake et al., 2013). Right after birth, the
children presented recurrent episodes of metabolic decompensa-
tion with lactic acidosis, hypoglycemia, hyperammonemia, and
ketosis but no neurological impairment or severe developmen-
tal delay. In fact, the clinical presentation resembled that of the
already reported UQCRBmutation (see above). The p.Arg183Trp
predicts to disrupt the protein structure at its hydrophobic core,
thus aﬀecting CIII stability. In agreement with this prediction, the
patient ﬁbroblasts showed a twofold reduction of CIII activity and
amount.
According to the CIII structure, Core 2 is facing the matrix
in close interaction with core 1 (UQCRC1). In the most recent
assembly model of the yeast bc1 complex, the core 2 subunit
(Qcr2) is proposed to interact with CYC1 to form one of the
assembly intermediates (Zara et al., 2009a; Figure 1).
Cytochrome c1
Mutations in one of the nuclear-encoded catalytic subunits,
CYC1 were proved to cause CIII deﬁciency in two unrelated
patients with similar clinical course (Gaignard et al., 2013). The
protein is a product of the CYC1 gene, located on chromosome
8q24 (OMIM 123980). The son of ﬁrst cousins of Lebanese ori-
gin was found to carry a homozygous c.288G>T transversion,
by whole-exome sequencing. The consequence of this change
is the substitution of an invariant tryptophan residue in posi-
tion 96 of the protein (p.Trp96Cys). The second patient, a
Sri Lankan girl also born to consanguineous parents, carried
another missensemutation in both alleles (c.643C>T)which pro-
duces a p.Leu215Phe amino acid change. Sequence alignment
of CYC1 from diﬀerent species proved the total conservation
of this residue throughout evolution. The main clinical feature
in both patients was the recurrent episodes of metabolic fail-
ure, usually after minor infections, with hypo or hyperglycemia
that was responsive to insulin treatment, and severe hyperlac-
tatemia. In both, neurodegenerative lesions were detected by
brain MRI whereas psychomotor regression during metabolic
crises was followed by complete recovery and overall normal
development.
Immunoblot analyses of ﬁbroblasts and skeletal muscle from
both patients showed low steady state levels of CYC1 and a CIII
assembly defect. Furthermore, both mutations were predicted to
disturb the protein structure, but showed to generate hypomor-
phic alleles since high copies of the mutant protein could rescue
the respiratory defect either in a deletion yeast strain or in the
patient cells.
Within CIII, CYC1 is anchored to the inner mitochondrial
membrane, and its C-terminus, containing the heme moiety,
faces the inter-membrane space. CYC1 receives the electrons
from UQCRFS1 to then transfer them to the mobile electron car-
rier cytochrome c (Iwata et al., 1998). In diﬀerent yeast strains
carrying deletions in structural subunits in which bc1 assembly is
arrested, it was shown that CYC1 interacts with Core 1 and Core
2 (Zara et al., 2007). This led the Authors to conclude that the
three subunits interact with each other early during CIII assem-
bly (Zara et al., 2009a; Figure 1). Considering the similarities in
CIII structure and assembly, this would explain the low UQCRC1
and UQCRC2 levels found in the CYC1 mutated ﬁbroblasts and
skeletal muscle (Gaignard et al., 2013).
Accessory Proteins: Assembly Factors
TTC19
TTC19 (OMIM 613814), located on chromosome 17p12, encodes
a protein shown to be involved in CIII biogenesis. The tetra-
tricopeptide repeat domain-containing protein 19 (TTC19) is
present in animals but absent in plants or yeast (Ghezzi et al.,
2011). The ﬁrst cases of CIII deﬁciency associated to TTC19
mutations were described in three patients from two unre-
lated Italian families with early-onset but slowly progressive
encephalopathy, and in a fourth patient with late-onset but
rapidly progressive neurological failure (Ghezzi et al., 2011).
Since the ﬁrst cases were reported, other TTC19 mutations have
been published always associated with isolated CIII but with
diﬀerent clinical presentations. A progressive neurodegenerative
disorder showing severe psychiatric signs and cerebellar disease
was found in four Portuguese siblings born to consanguineous
parents (Nogueira et al., 2013), Leigh syndrome was reported in
a Hispanic child (Atwal, 2013) and cerebellar ataxia in Japanese
adult individuals (Morino et al., 2014; Kunii et al., 2015). All
the described cases (Table 2) carried non-sense or frameshift
mutations leading to a truncated protein and, at least in the ﬁrst
reported patient samples, to undetectable TTC19 levels (Ghezzi
et al., 2011). However, the clinical output may vary in age of onset,
severity, and presence of psychiatric symptoms.
TTC19 was shown to co-immunoprecipitate and co-migrate
in Blue-Native Gel Electrophoresis (BNGE) with several CIII
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TABLE 2 | Summary of the clinical presentations and mutations in TTC19.
Phenotype TTC19 mutation Reported in
Early onset
Slowly progressive cognitive impairment and ataxia p.Leu219Ter Ghezzi et al. (2011)
Slowly progressive developmental delay and language regression, Leigh syndrome p.Trp186Ter/p.Gly322MetfsTer8 Atwal (2013)
Slowly progressive unsteady gait, learning difficulties, and behavioral alterations p.Gln77ArgfsTer30 Melchionda et al. (2014)
Late onset
Rapidly progressive neurological and psychiatric symptoms p.Gln173Ter Ghezzi et al. (2011)
Rapidly progressive psychiatric symptoms, ataxia and pyramidal signs p.Ala321fsTer8 Nogueira et al. (2013)
Rapidly progressive spinocerebellar ataxia and cognitive impairment p.Gln277Ter Morino et al. (2014)
Cerebellar ataxia, spastic paraparesis, loss of deep sensation, mild frontal lobe dysfunction and
transient psychiatric symptoms
p.Pro54AlafsTer48 Kunii et al. (2015)
structural subunits, suggesting physical interaction. Although its
exact function is currently unknown, a role as a chaperone in the
ﬁrst steps of CIII assembly is proposed for this protein, because a
proportion of unassembled UQCRC1 and UQCRC2 were found
in mutant muscle samples (Ghezzi et al., 2011). In addition,
a Ttc19-null Drosophila melanogaster model showed profound
CIII deﬁciency associated to neurological impairment in adult
individuals but, surprisingly, normal CIII activity in larvae, sug-
gesting developmental control of CIII assembly in ﬂies (Ghezzi
et al., 2011).
BCS1L
Mutations in BCS1L on chromosome 2q35 (OMIM 603647) are
still the most frequent cause of mitochondrial CIII isolated deﬁ-
ciency. BCS1L is a member of the AAA+ (ATPases associated
with diverse cellular activities) family of proteins. Yeast Bcs1 or
human BCS1L are needed for the ﬁnal steps of bc1 complex
assembly, where the Rieske Fe-S protein (Rip1 or UQCRFS1)
and the smallest subunit (Qcr10 or UQCR11) are incorporated
into the pre-CIII2 to complete the process (Nobrega et al., 1992;
Cruciat et al., 1999; Fernandez-Vizarra et al., 2007;Wagener et al.,
2011). Bcs1 is not exactly a chaperone, as it was demonstrated to
act as a translocase of the Rieske Fe-S protein (Rip1), moving it
from the matrix to the inner mitochondrial membrane through
interaction with the Rip1 N-terminal domain and ATP hydroly-
sis (Wagener et al., 2011; Cui et al., 2012). Bcs1 ATPase activity
seems to be necessary not only for its function but also to couple
the mitochondrial energy state to CIII biogenesis (Ostojic et al.,
2013).
BCS1L mutations (Figure 2) are associated with a wide
variety of clinical manifestations with diﬀerent tissue involve-
ment and disease progression (Table 3), ranging from multivis-
ceral GRACILE syndrome (growth retardation, aminoaciduria,
cholestasis, iron overload, lactic acidosis, and early death; OMIM
603358; Visapaa et al., 2002; Lynn et al., 2012; Kasapkara et al.,
2014); to congenital metabolic acidosis, neonatal proximal tubu-
lopathy and/or liver failure with or without encephalopathy (de
Lonlay et al., 2001; De Meirleir et al., 2003; Blazquez et al.,
2009; Gil-Borlado et al., 2009; Ramos-Arroyo et al., 2009; Ezgu
et al., 2013); to isolated severe mitochondrial encephalopathy
(Fernandez-Vizarra et al., 2007); to milder phenotypes such as
Björnstad syndrome (sensorineural hearing loss and pili torti;
OMIM 262000; Hinson et al., 2007; Siddiqi et al., 2013), a neu-
rological syndrome with long-term survival (Tuppen et al., 2010)
or neuro-psychiatric manifestations (Al-Owain et al., 2013).
In contrast to the other BCS1L mutations, no CIII deﬁciency
was originally reported for the GRACILE mutation, leading to
p.Ser78Gly change which is part of the Finnish heritage dis-
ease repertoire (Fellman, 2002). However, a more recent report
demonstrated decreased CIII amount and activity in liver, kid-
ney and heart of a GRACILE mutant patient (Kotarsky et al.,
2010). The other BCS1L mutations are indeed all associated
with CIII deﬁciency, either isolated or in combination with
reduced CIV and sometimes CI activities, with reduced amount
of UQCRFS1 and with accumulation of unstable pre-CIII2
(Fernandez-Vizarra et al., 2007; Hinson et al., 2007; Moran et al.,
2010).
The BCS1L protein contains several functional domains
(Figure 2) necessary for its activity and stability (Folsch et al.,
1996; Cruciat et al., 1999; Nouet et al., 2009): a transmembrane
helix, a mitochondrial signal peptide plus an import auxiliary
sequence, the AAA-domain and a Bcs1-speciﬁc sequence. Known
pathological mutations are scattered throughout the diﬀerent
regions of the BCS1L sequence, with the exception of the trans-
membrane domain (Figure 2). In addition, some mutations have
also been found in splice sites and in the 5′-UTR of the mature
BCS1L mRNA (Table 3). It is diﬃcult to relate the position of
the mutation to the pathological consequences at the biochemi-
cal and clinical levels. Most authors hypothesize that the clinical
variability shown by the BCS1L mutated patients must be due
to the nature of the amino acid substitution and its diﬀeren-
tial expression in diﬀerent tissues (Hinson et al., 2007; Kotarsky
et al., 2007; Ramos-Arroyo et al., 2009). Diﬀerent BCS1L muta-
tions, investigated in six patient-derived skin cultured ﬁbroblasts,
were found to impair a number of diﬀerent parameters, such as
CIII activity and assembly, import of the protein into mitochon-
dria, supramolecular associations of BCS1L, cell growth, shape of
the mitochondrial network, ROS levels and antioxidant defenses,
and apoptosis (Moran et al., 2010). Interestingly, the extent of the
functional alterations in cultured cells correlated with the severity
of the clinical presentation.
A consistent hallmark of GRACILE syndrome is liver iron
overload, leading to the proposal of a role for BCS1L in cellular
iron homeostasis (Visapaa et al., 2002). However, iron overload
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FIGURE 2 | Schematic representation of human BCS1L. Different coding exons and functional regions of the protein. TMD, trans-membrane domain; MTS:
mitochondrial targeting sequence; IAS: import auxiliary sequence. Positions and amino acid changes of the pathological mutations described up to date are also
depicted.
TABLE 3 | Summary of the clinical presentations and mutations in BCS1L.
Phenotype BCS1L mutation Reported in
Purely Visceral GRACILE syndrome p.Ser78Gly
p.Pro99Leu
Visapaa et al. (2002)
Kasapkara et al. (2014)
Complex III deficiency, lactic
acidosis, hepatopathy,
developmental delay, sensorineural
hearing loss
p.Thr50Ala Blazquez et al. (2009)
GRACILE + CIII
deficiency + neurological
symptoms
p.Arg56Ter/p.Val327Ala
Intron 1 -588T>A/Intron 2 321G>T
p.Ser78Gly/p.Arg144Gln
p.Arg56Ter/ Intron 1 -588T>A∗
Visapaa et al. (2002)
Lynn et al. (2012)
Complex III deficiency, tubulopathy,
encephalopathy and liver failure
p.Ser277Asn
p.Pro99Leu
p.Arg155Pro/p.Val353Met
p.Arg45Cys/p.Arg56Ter
g.1181A>G+g.1164C>G/p.Arg56Ter∗
de Lonlay et al. (2001)
De Meirleir et al. (2003)
Gil-Borlado et al. (2009)
Ramos-Arroyo et al. (2009)
Pure Encephalopathy Complex III deficiency,
encephalopathy, muscle hypotonia,
psychomotor delay, pili torti
p.Gly35Arg/p.Arg184Cys
p.Arg73Cys/p.Phe368Ile
p.Arg183Cys/p.Arg184Cys
Hinson et al. (2007)
Fernandez-Vizarra et al. (2007)
Milder Phenotypes Björnstad syndrome p.Arg183His
p.Ile106Ter (IVS2+1G>T)/p.Arg306His
p.Arg306His/p.Arg114Trp
p.Arg291Ter/p.Gln302Glu
p.Tyr301Asn
Hinson et al. (2007)
Siddiqi et al. (2013)
Muscle weakness, focal motor
seizures, optic atrophy,
long-survival
p.Gly129Arg Tuppen et al. (2010)
Behavioral alterations,
hypomania/psychosis
p.Gly129Arg Al-Owain et al. (2013)
is present in some non-GRACILE cases and absent in others
(Ramos-Arroyo et al., 2009; Moran et al., 2010). To better char-
acterize the pathophysiological consequences of the GRACILE
mutation, a knock-in mouse has been created, being the only
viable animal model of CIII deﬁciency reported to date (Leveen
et al., 2011). Homozygous mutant mice show growth retarda-
tion starting at 3 weeks and eventually die before 6 weeks from
birth. They show progressive hepatopathy and profound CIII
deﬁciency in liver, and to a lesser degree in heart and kidney
as well. Interestingly, whilst the levels of Bcs1l in homozygous
mutant liver and kidney were very low at any age, the amount
of Uqcrfs1 incorporated into CIII2 progressively decreased over
time, becoming almost undetectable just before death.
MZM1L (LYRM7)
Human LYRM7, located on chromosome 5q23.3 (OMIM
615831), encodes the LYR (leucine/tyrosine/arginine)-motif pro-
tein 7, a member of the Complex1_LYR-like superfamily
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(Angerer, 2013). LYR motifs are the molecular signature of pro-
teins that contain or assist in the delivery of Fe-S clusters (Maio
et al., 2014). LYRM7 is highly homologous to the yeast protein
Mzm1, which was originally described as necessary to main-
tain the mitochondrial pool of zinc (Atkinson et al., 2010),
but was later demonstrated to be an assembly factor speciﬁc
to the bc1 complex (Atkinson et al., 2011; Cui et al., 2012).
The human protein can functionally complement the respira-
tory defect of a Mzm1-deleted yeast strain (Sanchez et al., 2013).
Because of the similarities between both proteins, we proposed
MZM1L as an alternative name for LYRM7 (Sanchez et al.,
2013).
As already mentioned, the last step in CIII assembly involves
the incorporation of Rip1/UQCRFS1 protein into CIII in the
inner mitochondrial membrane after it has been imported into
the matrix, processed to a mature form and endowed with a 2Fe-
2S cluster cofactor (Hartl et al., 1986). The yeast and human
proteins work as a stabilizing chaperone of the Rieske protein in
the mitochondrial matrix, interacting with its C-terminal domain
and holding it there prior to its translocation to the inner mito-
chondrial membrane and incorporation to CIII (Cui et al., 2012;
Sanchez et al., 2013). A possible role for LYRM7 in Fe-S clus-
ter delivery is also suggested by its interaction with the HSC20
cochaperone (Maio et al., 2014).
Genetic screening of LYRM7 in unresolved cases of CIII deﬁ-
ciency, led to the identiﬁcation of a homozygous c.73G>A tran-
sition, which predicts a p.Asp25Asn amino acid change. Yeast
studies conﬁrmed the pathogenicity of the mutation (Invernizzi
et al., 2013). The aﬀected child was born toMoroccan healthy ﬁrst
cousins. Her development was normal until 20 months of age,
when she presented progressive weakness with anemia associated
with low plasma iron. A month later, during a febrile infection,
she developed severe encephalopathy and metabolic acidosis.
Severe psychomotor regression persisted until 28 months of age,
when she died of respiratory failure.
To further characterize the molecular function of MZM1L,
we performed RNAi experiments in HeLa cells (Figure 3A).
Similar to the Mzm1 deletion yeast strain (Atkinson et al.,
FIGURE 3 | MZM1L RNA interference experiments in HeLa cells. Five
different shRNA sequences cloned in the pLKO.1 lentiviral vector
(TRCN0000064433-37), purchased from the MISSION R© shRNA Library
(Sigma-Aldrich) were stably transduced. (A) The steady state levels of the
indicated proteins were quantified by SDS-PAGE, Western blot and
immunodetection with specific antibodies: anti-LYRM7 (MZM1L) and Actin
(Sigma-Aldrich) and UQCRFS1 and UQCRC2 (Mitosciences-Abcam). Actin
was used as the normalizer/loading control. The shRNA sequences...33,
. . .36, and . . .37 were the most efficient in knocking down MZM1L
expression. (B) Blue-Native PAGE, Western blot and immunodetection
analysis of knocked down and control digitonin-treated cells (Nijtmans et al.,
2002) grown either at 37◦C or at 42◦C for 24 h. Anti-MTCO1 was from
Mitosciences-Abcam. (C) Spectrophotometric CIII and CIV enzyme activities
of the RNAi and control cells grown either at 37◦C or at 42◦C for 24 h.
∗p < 0.05 according to the ANOVA Post-Hoc LSD test (SPSS 16.0 software
for Windows).
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2011), low levels of MZM1L caused a decrease in the total
amount of UQCRFS1 (Figure 3A), while UQCRC2 was unaf-
fected. However, in normal culture conditions, the amount of
UQCRFS1 incorporated into CIII2 and the CIII enzyme activ-
ity was the same as in control cells (Figures 3B,C). Only by
exposing the interfered cells to heat stress (incubation at 42◦C
for 24 h) was the reduced CIII assembly and activity manifested
(Figures 3B,C). Thus, the absence of MZM1L makes UQCRFS1,
unstable but only the fraction residing in the matrix that has not
been assembled into the complex. These results support the idea
that MZM1L is necessary to stabilize UQCRFS1 in the matrix
but is not involved in its translocation, which is virtually nor-
mal even when MZM1L is absent. Similar to Mzm1-deﬁcient
yeast (Atkinson et al., 2011), the phenotype is thermo-sensitive,
probably because at high temperatures the unassembled Rieske
protein is more prone to degradation and/or aggregation (Cui
et al., 2012). This could explain why the clinical course drastically
worsened in the LYRM7 mutated patient after a febrile episode
(Invernizzi et al., 2013).
UQCC2
Sequencing the “MitoExome,” i.e., through the speciﬁc capture
of both mtDNA and ∼1,000 nuclear genes encoding (part of)
the mitochondrial proteome (Calvo et al., 2012), a mutation in
UQCC2 (C6orf125; OMIM 614461) was discovered in a patient
with profound CIII deﬁciency (Tucker et al., 2013). This subject
also presented secondary reduction in CI and CIV activities. The
mutation, found in homozygosis in exon 2 (c.214-3C>G), caused
altered splicing of the transcript and the absence of the protein
(Tucker et al., 2013). The consequence for the patient, a boy
born to consanguineous Lebanese parents, was severe metabolic
acidosis documented 12 h after birth. He also had dysmorphic
features, delayed neurological development and sensorineural
hearing impairment, and later developed autistic features and
aggressive behavior. He was alive at 9 years of age when clinical
follow-up was lost.
UQCC2 is the ortholog of yeast Cbp6, which interacts with
Cbp3, homolog to human UQCC1. UQCC2 and UQCC1 were
also shown to interact, because the presence of one is required
for the stability of the other (Tucker et al., 2013). The two pro-
teins co-migrate in Blue-Native gels (Figure 4), showing a pattern
very similar to the yeast proteins (Gruschke et al., 2011, 2012;
FIGURE 4 | Co-migration of human UQCC1 and UQCC2 in Blue-Native
PAGE. Mitoplasts from HeLa cells were solubilized using either 1%
dodecylmaltoside (DDM) or 2% digitonin and then run through a
NativePAGETM 3–12% native gel (Life Technologies). After the lanes were
excised, treated with denaturing solution and run through a NuPAGETM
4–12% Bis-Tris denaturing gel (Life Technologies). The gels were then
transferred to PVDF membranes and immunoblotted with antibodies
recognizing UQCC1 (UQCC) and UQCC2 (MNF1) both from Abcam.
Hildenbeutel et al., 2014). In yeast mitochondria, the Cbp3–Cbp6
complex binds to the mitochondrial ribosome exit tunnel where
it is necessary for the eﬃcient synthesis of cytochrome b and the
ﬁrst steps of bc1 complex assembly (Gruschke et al., 2011, 2012).
Furthermore, the Cbp3–Cbp6 complex regulates cytochrome b
synthesis linking it to its assembly, because once the translation
of cytochrome b is completed, the Cbp3–Cbp6 complex remains
bound to the peptide in the mitochondrial inner membrane while
another protein, Cbp4, is recruited. Unless other structural sub-
units (Qcr7 and Qcr8) bind to cytochrome b, the Cbp3–Cbp6
complex is sequestered and cannot bind again to the ribosome to
activate the synthesis and release of new cytochrome b (Gruschke
et al., 2011, 2012; Hildenbeutel et al., 2014).
Similar to Cbp6-deleted yeast model, UQCC2-deﬁcient cells
show greatly reduced MT-CYB synthesis, whereas the amount
of CIII is recovered when the wild-type protein is expressed
(Tucker et al., 2013). The same report demonstrated the
physical interaction between UQCC2 and newly synthesized
MT-CYB.
UQCC3
Bioinformatics analyses predicted that the protein encoded
in the C11orf83/UQCC3 gene might be the ortholog of the
yeast protein Cbp4, another cytochrome bc1 complex assem-
bly factor (Wanschers et al., 2014). Mutational screening in
a patient showing isolated CIII deﬁciency in skeletal mus-
cle, revealed the presence of a homozygous c.59T>A muta-
tion producing a p.Val20Glu amino acid change, in a position
where there are only hydrophobic residues in other metazoan
homologs. Both parents were consanguineous, and heterozy-
gous for the mutation. The patient showed very early-onset
symptoms, presenting hypoglycemia and severe lactic acido-
sis already in the ﬁrst day of life. She suﬀers from mus-
cle weakness from birth, with severely delayed psychomotor
development. Biochemically, cultured ﬁbroblasts showed very
reduced levels of assembled CIII and low MT-CYB synthesis and
stability.
Yeast Cbp4 assists the ﬁrst steps of CIII assembly, binding to
the cytochrome b-Cbp3-Cbp6 intermediate once it is released
from the mitoribosome, but is not required for cytochrome b
translation (Gruschke et al., 2012). These interactions can occur
only once the bL site of cytochrome b has been hemylated
(Hildenbeutel et al., 2014).
There are strong indications that the mutation found in the
reported patient is pathogenic: the type of amino acid change,
which makes the protein unstable; its absence in a number of
controls; and segregation with the disease (Wanschers et al.,
2014). Also, the prediction of UQCC3 as being the Cbp4 ortholog
explains the CIII deﬁciency. However, UQCC3 is shorter than
Cpb4 (93 vs. 147 amino acids) and their C-terminal sequences are
not homologous. Furthermore, human UQCC3 presents a diﬀer-
ent topology insidemitochondria and is not able to complement a
Cbp4-deﬁcient yeast strain (Wanschers et al., 2014). In addition,
knocked-down expression by RNAi in control cells did not aﬀect
CIII assembly or activity and the patient’s CIII defect in ﬁbrob-
lasts could not be rescued by expression of exogenous wild-type
recombinant UQCC3.
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Concluding Remarks
Although the genetic deﬁnition of CIII deﬁciency has remark-
ably expanded in the last 5 years, ∼50% of the cases remain
genetically unsolved. This is likely due to a still sketchy under-
standing of the assembly process of CIII and limited knowledge
of the speciﬁc assembly factors required for this process to be
completed. As stated above, the model currently favored for CIII
assembly (Figure 1) is based on studies in S. cerevisiae, but sev-
eral lines of evidence supports the idea that a very similar process
occurs in humans (Fernandez-Vizarra et al., 2007; Sanchez et al.,
2013; Tucker et al., 2013). Nevertheless, even in yeast mechanis-
tic understanding has been achieved only for the initial and ﬁnal
steps of the process, i.e., the events just following the de novo syn-
thesis of cytochrome b (Gruschke and Ott, 2010; Gruschke et al.,
2011, 2012; Hildenbeutel et al., 2014) and the incorporation of
the Rieske protein which rapidly leads to assembly completion
(Atkinson et al., 2011; Wagener et al., 2011; Cui et al., 2012).
Whilst OXPHOS accessory proteins that directly interact with
structural subunits seem to be conserved from yeast to humans,
other factors, for instance TTC19, do not appear to have yeast
orthologs (Ghezzi et al., 2011). This reﬂects evolutionary diver-
gence as well as the diﬀerences in the mitochondrial genetic
system andMRC organization between yeast andmetazoans. The
most obvious dissimilarity is the presence in mammals of the
multimeric complex I and its interaction with CIII and CIV, to
form the so-called supercomplexes or respirasomes (Acin-Perez
et al., 2008; Moreno-Lastres et al., 2012; Lapuente-Brun et al.,
2013). The easy geneticmanipulation and the metabolic ﬂexibility
of S. cerevisiae, a facultative fermentative organism, make it an
extremely useful model to study OXPHOS biogenesis. By genetic
data mining and phylogenetic analysis, yeast factors have been
key to discover human orthologs and model in yeast some of
the mutations found in patients (Barrientos, 2003; Meunier et al.,
2013), including assembly factors and chaperones such as BCS1L
(de Lonlay et al., 2001; Visapaa et al., 2002; Fernandez-Vizarra
et al., 2007; Nouet et al., 2009; Meunier et al., 2013) and MZM1L
(Invernizzi et al., 2013).
A next, formidable challenge will be to unravel the mecha-
nisms and factors speciﬁc to mammalian CIII biogenesis. In this
respect, the genetic characterization of CIII defective subjects, by
NGS technology, and new tools oﬀered by proteomic techniques
applied to human cells and animal models will be fundamental to
make progress in this ﬁeld.
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